(VSTM) Verastem, Inc. Business Model Canvas Research

RAMP 201 and RAMP 202 depend on multicenter trial sites because these studies need fast enrollment, consistent dosing, close safety monitoring, and clean data capture across rare, biomarker-defined cancers. In oncology, that site network is the operating backbone; without it, Verastem, Inc. cannot scale patient recruitment or keep protocol execution tight.

• Supports enrollment across multiple centers
• Manages dosing and safety checks
• Captures trial data in real time
• Critical for rare-cancer recruitment

Verastem, Inc. relies on CROs, CMOs, and suppliers to run its clinical-stage work, so it can outsource trial operations, drug manufacturing, and supply chain tasks instead of building heavy in-house infrastructure. This model keeps fixed costs lighter while letting Verastem focus cash on development of its oncology pipeline.

• Outsourced trials cut internal overhead
• CMOs handle drug production
• Suppliers support clinical supply flow

Safety and efficacy analysis is central to Verastem’s RAMP 201, a 3-part adaptive study where ongoing review of safety, tolerability, and tumor response guides dose choice, expansion, and next-step decisions. That matters because clinical readouts can shift after each interim review, so the team keeps re-testing the balance between benefit and risk before moving the program forward.

• 3-part adaptive trial design
• Tracks safety, tolerability, response
• Drives dose and expansion decisions

Verastem, Inc. must coordinate FDA/EMA interactions, protocol updates, and GMP supply so each study runs with the right drug, labels, and site readiness. This is a core clinical-stage task in 2025, when commercialization depends on clean filings and uninterrupted trial inventory.

• Aligns trials, filings, and supply
• Supports FDA-ready commercialization
• Reduces delays in late-stage studies

RAMP 201, RAMP 202, and RAMP 203 generate proprietary clinical evidence on avutometinib-based regimens, including biomarker-defined response data that Verastem, Inc. can use in FDA and partner talks. In 2025, Verastem, Inc. reported 3 active RAMP studies as core assets for trial design and execution.

• Proprietary efficacy and safety data
• Biomarker criteria and protocol know-how
• Regulatory and partnering support

Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts. Its in-house oncology team covers scientific, clinical, regulatory, and business development work, which is essential for a development-stage company running late-stage cancer programs.

• Founded: 2010
• HQ: Needham, Massachusetts
• Core team: science, clinical, regulatory, BD
• Supports development-stage oncology execution

Verastem, Inc.'s biomarker defined lung cancer option targets NSCLC patients with KRAS and BRAF mutations after platinum and checkpoint inhibitor therapy, a niche where KRAS drives about 25% of NSCLC and BRAF about 2%. The RAMP 202 program is aimed at patients who have already used standard care, so the value proposition is clear unmet need plus mutation-based selection.

• KRAS NSCLC: about 25%
• BRAF NSCLC: about 2%
• Post-platinum, post-checkpoint setting
• Biomarker-driven patient selection

Verastem’s combination science platform uses defactinib with LUMAKRAS to target MAPK-linked signaling, aiming for synergy across tumor-driving pathways. This model is built to extend across multiple tumor types as new clinical data read out, which matters because the U.S. market for KRAS-mutant cancer remains large and still has few durable treatment options.

• Combines defactinib plus LUMAKRAS
• Targets MAPK pathway synergy
• Designed for multiple tumor types

Verastem, Inc. keeps oncologists and researchers close through medical and scientific exchange, sharing trial readouts, safety updates, and efficacy data so they can judge its assets with current evidence. This matters because confidence in a clinical profile depends on repeated disclosure, not one-off headlines.

• Trial disclosures
• Safety and efficacy updates
• Scientific engagement
• Builds clinician confidence

Verastem, Inc. uses regular investor updates to keep the market on trial progress, partnership news, and capital needs. In Q1 2025, it held $112.4 million in cash and equivalents, so clear investor communication still matters for funding a pipeline with no product revenue.

• Frequent updates reduce uncertainty
• Trial milestones move the share price
• Cash access depends on market trust

Scientific conferences are a key channel for Verastem, Inc. because each poster or oral update can put trial data in front of oncologists, researchers, and investors at the same time. In 2025, this matters even more for a small-cap biotech, where conference visibility can move awareness faster than paid media and helps build trust around pipeline milestones.

Presenting at meetings such as ASCO or ESMO lets Verastem share efficacy and safety updates directly, which supports credibility and keeps its clinical story current.

• Shares trial data fast
• Reaches key clinicians
• Builds scientific credibility

Partner commercialization channels can extend Verastem, Inc. beyond its own sales reach, especially through licensing deals for regional launch. The Chugai collaboration is a clear example: it can open access to Japan and other partner-led markets if approval comes.

• Extends reach without building a full field force
• Shares launch risk and local execution costs
• Becomes more valuable after approval

Cancer centers and hospitals are the main clinical gatekeepers for Verastem, Inc., because they administer oncology therapy and run trial enrollment; WHO/IARC estimated 20 million new cancer cases and 9.7 million deaths worldwide in 2022, so access at these sites drives adoption fast.

• Clinical users and operational buyers
• Control treatment access and trial flow
• Key to adoption and reimbursement

Verastem, Inc. also sells to pharma partners and licensees through licensing and co-development deals. These B2B counterparties value access to key programs such as VS-6766 and FAK-targeted assets, which support pipeline expansion and shared development risk.

• 2 core partner assets: VS-6766 and FAK programs
• Revenue comes from licensing and co-development
• Partners seek pipeline access and shared risk

Verastem, Inc.’s general and administrative cost is the public-company overhead that supports finance, legal, compliance, and investor relations, plus headquarters costs in Needham, Massachusetts. This base cost stays in place even before product sales scale, so it is a key drag on operating margin.

• Staffing and finance support
• Legal, compliance, investor relations
• Needham HQ rent and admin

Verastem, Inc. must fund patent filings, license tracking, and FDA/EMA meetings because a development-stage biotech lives on protected IP and clean regulatory execution. These costs protect the platform’s long-term value, and they usually sit inside R&D and G&A spending in the latest annual filing.

• Patent protection keeps future upside exclusive.
• Licensing work adds legal and admin cost.
• Agency talks are a fixed biotech burden.

If VS-6766 based therapies win approval, Verastem, Inc. could add direct oncology product sales as a major revenue stream. Today, this is still a future option: the Company has not yet launched an approved VS-6766 therapy, so product revenue remains at 0.

• Approval would unlock direct commercialization
• Revenue today is still future-only
• Oncology sales could become material

Research reimbursements come from collaborative deals that can cover part of Verastem, Inc.'s development and research spend, helping offset trial costs and keep pipeline work moving. In FY2025, this revenue stream is still tied to partner activity, so cash inflows can be uneven but directly support ongoing program advancement.

• Offsets R&D and trial spend
• Depends on partner agreements
• Supports pipeline progression